| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
25064 |
| Drug |
Belantamab mafodotin |
| Brand |
Blenrep® |
| Indication |
Belantamab mafodotin (Blenrep®) is indicated in adults for the treatment of relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. |
| Rapid review commissioned |
29/10/2025 |
| Rapid review completed |
01/12/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness compared with the current standard of care. |
| Full HTA commissioned by the HSE |
19/12/2025 |
